PRODUCTS SERVICES COMPANY CONTACT FAQ

Search Dictionary Mobile

Login

Mohamad Navab Selected Research

Atherosclerosis (Atheroma)

02/2008	The effect of apolipoprotein mimetic peptides in inflammatory disorders other than atherosclerosis.
06/2007	Adenovirus-mediated expression of human paraoxonase 3 protects against the progression of atherosclerosis in apolipoprotein E-deficient mice.
12/2006	Adenovirus mediated expression of human paraoxonase 2 protects against the development of atherosclerosis in apolipoprotein E-deficient mice.
10/2006	Paraoxonase-2 deficiency aggravates atherosclerosis in mice despite lower apolipoprotein-B-containing lipoproteins: anti-atherogenic role for paraoxonase-2.
10/2006	Apolipoprotein A-I mimetic peptides and their role in atherosclerosis prevention.
08/2006	Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis.
10/2005	Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation.
09/2005	Oral small peptides render HDL antiinflammatory in mice and monkeys and reduce atherosclerosis in ApoE null mice.
09/2005	An oral apoJ peptide renders HDL antiinflammatory in mice and monkeys and dramatically reduces atherosclerosis in apolipoprotein E-null mice.
01/2005	The paraoxonase gene family and atherosclerosis.
12/2004	Human apolipoprotein A-I and A-I mimetic peptides: potential for atherosclerosis reversal.
06/2004	The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL.
10/2003	Oral synthetic phospholipid (DMPC) raises high-density lipoprotein cholesterol levels, improves high-density lipoprotein function, and markedly reduces atherosclerosis in apolipoprotein E-null mice.
09/2003	Human apolipoprotein AI mimetic peptides for the treatment of atherosclerosis.
04/2003	Increased low-density lipoprotein oxidation and impaired high-density lipoprotein antioxidant defense are associated with increased macrophage homing and atherosclerosis in dyslipidemic obese mice: LCAT gene transfer decreases atherosclerosis.
01/2002	Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol.

Articles by Research Topic

Disease

16	Atherosclerosis (Atheroma) 02/2008 - 01/2002
4	Inflammation 04/2008 - 05/2005
2	Human Influenza (Influenza) 11/2004 - 08/2002
2	Infection 11/2004 - 08/2002
1	Leprosy (Hansen's Disease) 08/2008
1	Experimental Arthritis 05/2008
1	Stroke (Strokes) 03/2007
1	Rheumatoid Arthritis 08/2006
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 08/2006
1	Acute-Phase Reaction 08/2006
1	Coronary Disease (Coronary Heart Disease) 08/2002
1	Coronary Artery Disease (Coronary Atherosclerosis) 06/2002

Drug/Important Bio-Agent (IBA)

9	Apolipoprotein A-I (Apolipoprotein A1)IBA 05/2008 - 01/2002
7	ApolipoproteinsIBA 02/2008 - 06/2002
6	PeptidesIBA 04/2008 - 09/2003
6	Lipoproteins (Lipoprotein)IBA 04/2008 - 04/2003
5	Aryldialkylphosphatase (Paraoxonase)IBA 06/2007 - 06/2002
2	PhospholipidsIBA 08/2008 - 06/2004
2	HDL CholesterolIBA 03/2007 - 10/2003
2	CholesterolIBA 10/2005 - 01/2002
1	Pravastatin (Pravachol)FDA LinkGeneric 05/2008
1	Messenger RNA (mRNA)IBA 01/2008
1	LDL Receptors (LDL Receptor)IBA 01/2008
1	Sterol Regulatory Element Binding Protein 1IBA 01/2008
1	HDL LipoproteinsIBA 08/2006
1	Apolipoproteins E (ApoE)IBA 09/2005
1	Dimyristoylphosphatidylcholine (DMPC)IBA 10/2003
1	LipidsIBA 08/2002
1	Amino Acids FDA Link 01/2002